Second Life for Cytology Samples: How Repurposing Old Specimens is Revolutionizing Molecular Testing
"Unlock Hidden Insights: Discover how molecular cytopathology transforms residual samples into valuable diagnostic tools, enhancing precision medicine and patient care."
The field of cytopathology is undergoing a major transformation, driven by the increasing use of molecular techniques in routine clinical practice. From traditional methods like HPV testing and urine analysis to cutting-edge nucleic acid and protein-based assays, molecular cytopathology is playing an increasingly important role in medical decision-making. This evolution, however, presents a significant challenge: the need to extract more information from limited tissue samples obtained through minimally invasive procedures like fine-needle aspiration (FNA).
Fortunately, the versatility of cytology specimen preparations offers a solution. Cytopathologists are pioneering innovative methods to derive genomic insights from even the smallest samples, including the often-overlooked residual cytologic substrates. For years, residual liquid-based cytology (LBC) preparations from gynecological samples have been used for high-risk HPV detection. LBC media not only preserves cellular morphology for accurate diagnosis but also safeguards nucleic acids for downstream DNA and RNA analysis.
This practice is now expanding to non-gynecological FNA samples, with promising results. Studies have demonstrated the feasibility of extracting nucleic acids from residual LBC solutions of thyroid FNA specimens for mutation analysis. These analyses employ sophisticated techniques like high-resolution melting polymerase chain reaction (PCR), pyrosequencing, and next-generation sequencing (NGS) to identify critical genetic alterations.
A Reliable Tool for Cancer Biomarker Testing
Ancillary and molecular testing of cytopathology specimens has emerged as a reliable and useful tool, providing both diagnostic information and treatment-related biomarker status for the management of cancer patients. The field has built its own literature base: the journal Diagnostic Cytopathology invites original observations based on translational research, molecular testing, and the identification of targets for novel forms of treatment. Reporting practices are also being tightened, with revisions to statistical record requirements clarifying the collection of data on gynecologic cytopathology cases reported by diagnosis for each specimen type. Dedicated reference resources, such as the molecular cytopathology topic on PathologyOutlines, reflect the growing formalization of this area of practice.
Cytology as the Standard Route for Molecular Testing
Molecular diagnostics has expanded to become the standard of care for a variety of solid tumor types, and with limited diagnostic material it is often desirable to use cytological preparations to provide rapid and accurate molecular results. This trend is driven in part by the realities of advanced disease: in many types of advanced cancers, including non-small cell lung cancer (NSCLC), cytological samples often provide the diagnostic material of choice. Yet the field still faces a teaching gap, with observers noting the disconnect between the increasing importance of molecular diagnostics and the predominantly morphology-based approach of histopathology and cytopathology, prompting calls for integrated teaching of molecular and morphologic methods.
A Decade of Integration: From Morphology to Molecular
In the last decade, molecular cytopathology has emerged as a rapidly evolving field of diagnostic and predictive pathology, with an increasing number of molecular tests performed with high versatility on a range of cytological preparations. The approach integrates genetic and molecular techniques with traditional cytology, enabling analysis of genetic mutations, gene expression, and protein markers in cells for a more comprehensive understanding of disease. Practitioners argue that a continuous educational effort and timely updates in both clinical and methodological molecular cytopathology are required to better exploit the role of this approach in molecular medicine. The growing body of edited volumes on molecular histopathology and cytopathology reflects the field's consolidation as a distinct discipline.
Repurposing Residual Samples: A Step-by-Step Guide
One notable study detailed the use of residual PreservCyt specimens from FNA samples and body fluids to extract DNA for multigene NGS analysis. Another study explored the use of residual CytoLyt from endobronchial ultrasound-guided transbronchial needle aspirates for NGS evaluation. These methods showcase the potential of extracting valuable genetic information from what was previously considered waste material.
- Maximizes the use of limited tissue.
- Reduces the need for additional biopsies.
- Provides comprehensive genomic information.
- Improves diagnostic accuracy.
A Growing Literature on Molecular Applications
A concise handbook titled Molecular Cytopathology reviews the current applications of molecular tools in cytopathology and is positioned for those providing care in this era of personalized medicine, with the same volume echoed in the research community as a practical reference for the field. Dedicated journals such as Cancer Cytopathology, an international cytopathology journal, continue to publish research related to the etiology of cancer, its diagnosis, and its prevention, providing an ongoing outlet for molecular cytopathology findings. Together these venues give clinicians and researchers a steady stream of reviews and primary studies to guide biomarker testing on cytology specimens.
Molecular Approaches Versus the Limits of Cells
While cytopathology specimens have a major role in diagnosing patients with advanced diseases—a population where predictive molecular testing is now the standard of care for a growing number of tumor types—some argue that molecular approaches offer key advantages over cell-based analysis. Chief among these is the ability to analyze cell-free molecules, such as circulating tumor DNA, without requiring intact cells. This positions molecular testing as both a complement and a potential alternative in settings where cells are scarce or degraded, underscoring that cytology's central role must be understood within a broader molecular testing ecosystem.
Molecular Methods Versus Morphology in Practice
Direct comparisons between molecular and morphologic approaches help clarify when each method is best deployed. One widely cited review presents a table comparing a molecular method—Hybrid Capture—with morphology-based cytology for cervical cancer screening in large populations, illustrating how assay choice depends on population scale and throughput. Complementary work by Roy-Chowdhuri defines the scope and clinical utility of molecular diagnostic cytopathology, with emphasis on the interpretation of molecular diagnostic results and how they correlate with cytologic findings. Together, these analyses frame molecular and morphologic methods as complementary rather than competing tools in the cytology laboratory.
The Future of Cytopathology
In an era where resources are precious, and the demand for comprehensive genomic information is ever-increasing, cytopathologists must embrace innovative approaches. Repurposing discarded cytology samples offers a path forward, allowing for better utilization of available resources and improved patient care. As with any clinical diagnostic assay, it is crucial to optimize preanalytic aspects of specimen processing and validate tests before implementation. However, the ability to detect clinically relevant genetic alterations from previously discarded samples introduces a new dimension to cytopathology, enhancing its role in precision medicine.
Expert Consensus on Governance and Quality
Expert opinion on NSCLC small specimen biomarker testing, issued on behalf of IQN Path ASBL, highlights important administrative and legal considerations when using cytopathological samples for molecular diagnostic analysis. The experts recommend that laboratories define clear policies for the partial or complete use of cytopathology slides, balancing diagnostic needs with regulatory requirements. On the commercial side, services such as cytopathology expert opinion testing advertise transparent pricing and turnaround time commitments, signaling that access to expert review is being formalized for broader clinical use.
Publication Pipelines for the Next Wave
Looking ahead, the direction of molecular cytopathology will be shaped by the research venues that carry its findings. Cancer Cytopathology is an international cytopathology journal publishing research related to the etiology of cancer, its diagnosis, and its prevention, making it a natural outlet for new molecular applications. As molecular assays expand across more tumor types, such journals help translate laboratory advances into routine diagnostic practice and help set the agenda for the next generation of tests.
Converging Technologies Reshape the Discipline
A Frontiers in Medicine editorial positions molecular cytopathology within a broader technological landscape that includes next generation sequencing, epigenetic analyses, digital pathology, and predictive immunohistochemistry. The convergence of these tools signals that cytopathology is no longer a morphology-only discipline but part of an integrated molecular workflow. This framing implies systemic changes—new platforms, data handling, and quality systems—that laboratories must absorb as the field matures and molecular applications become more routine.
Real-World Validation Touches Real Patients
Molecular cytopathology is a rapidly evolving field embracing both conventional microscopy and molecular pathology, and its growing popularity stems from the fact that in many types of advanced cancers, including non-small cell lung cancer (NSCLC), cytological samples are central to care. The real-world impact is measurable: the first external, independent, prospective, real-world, observational, and non-interventional validation study of a microRNA thyroid classifier analyzed 256 patients with nodules classified as Bethesda III/IV. Such studies move molecular cytopathology beyond the research bench and into everyday clinical decisions for individual patients.